Clinical and in vitro resistance to GS-9669, a Thumb Site II nonnucleoside inhibitor of the hepatitis C Virus NS5B Polymerase

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6599-6606

  Dvory Sobol, Hadas ^a   Voitenleitner, Christian ^a   Mabery, Eric ^a,c   Skurnac, Taylor ^a   Lawitz, Eric J ^b   McHutchison, John ^a   Svarovskaia, Evguenia S ^a   Delaney, William ^a   Miller, Michael D ^a   Mo, Hongmei ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Reset Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FILIBUVIR; GS 9669; LEDIPASVIR; LOMIBUVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; SOFOSBUVIR; TEGOBUVIR; UNCLASSIFIED DRUG; VEDROPREVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; FURAN DERIVATIVE; GS-9451; GS-9669; NS-5 PROTEIN, HEPATITIS C VIRUS; PROTEIN BINDING; QUINOLINE DERIVATIVE; THIOPHENE DERIVATIVE; URIDINE PHOSPHATE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG MEGADOSE; DRUG SUBSTITUTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; REPLICON; TREATMENT DURATION; VIRUS ISOLATION; ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC VARIATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; MICROBIAL SENSITIVITY TEST; MOLECULAR GENETICS; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; BENZIMIDAZOLES; CELL LINE; DRUG RESISTANCE, VIRAL; FEMALE; FLUORENES; FURANS; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; QUINOLINES; RIBAVIRIN; SEQUENCE ANALYSIS, RNA; SOFOSBUVIR; THIOPHENES; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84908617711     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02815-14     Document Type: Article

References (23)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010 .03432.x
2. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374. http://dx.doi.org/10.1002/hep.22759
3. Di Bisceglie AM, McHutchison J, Rice CM. 2002. New therapeutic strategies for hepatitis C. Hepatology 35:224-231. http://dx.doi.org/10 .1053/jhep.2002.30531
4. Manns MP, Wedemeyer H, Cornberg M. 2006. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350-1359. http://dx.doi.org/10.1136/gut.2005.076646
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitisCvirus infection. N. Engl. J. Med. 347:975-982. http://dx.doi.org/10.1056/NEJMoa020047
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. http://dx.doi.org/10.1016/S0140-6736(01)06102-5
7. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839-1850. http://dx.doi.org/10.1056/NEJMoa0807650
8. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 Investigators. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716. http://dx.doi.org/10.1016/S0140-6736(10)60934-8
9. Imhof I, Simmonds P. 2011. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53:1090-1099. http://dx.doi.org/10.1002/hep.24172
10. Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. 2011. Telaprevir alone or with peginterferon and ribavirin reducesHCVRNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141:881-889.e1. http://dx.doi.org/10.1053/j.gastro.2011.05.046
11. Fenaux M, Eng S, Leavitt SA, Lee YJ, Mabery EM, Tian Y, Byun D, Canales E, Clarke MO, Doerffler E, Lazerwith SE, Lew W, Liu Q, Mertzman M, Morganelli P, Xu L, Ye H, Zhang J, Matles M, Murray BP, Mwangi J, Zhang J, Hashash A, Krawczyk SH, Bidgood AM, Appleby TC, Watkins WJ. 2013. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 57:804-810. http://dx.doi.org/10.1128/AAC .02052-12.
12. Lawitz E, Hazan L, Gruener D, Hack H, Backonja M, Hill J, German P, Dvory-Sobol H, Jain A, Arterburn S, Watkins W, Rossi S, McHutchinson J, Rodriguez-Torres M. 2012. GS-9669, a novel NS5B non-nucleoside thumb site II inhibitor, demonstrates potent antiviral activity, favorable safety profile and potential for once-daily dosing; poster 1189. 47th Ann. Meet. Eur. Assoc. Study Liver (EASL), Barcelona, Spain, 18 to 22 April 2012
13. Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M. 2012. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob. Agents Chemother. 56:1331-1341. http://dx.doi.org/10.1128/AAC.05611-11
14. Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Pürstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W. 2011. Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55:4196-4203. http://dx.doi.org/10.1128/AAC.00307-11
15. Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE, IV. 2010. Novel HCV reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob. Agents Chemother. 54:3099-3106. http://dx.doi.org/10.1128/AAC.00289-10
16. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. http://dx.doi.org/10.1126/science.285.5424.110
17. Choe S, Han D, Cheng M, Anton E, Stawiski E, Penuel E, Parkin N, Petropoulos CJ, Reeves JD. 2010. Validation of the GeneSeq HCV NS5B sequencing assay for patient-derived HCV subtypes 1a and 1b. Abstr. 45th Ann. Meet. Eur. Assoc. Study Liver. http://www.natap.org/2010/EASL/EASL-67.htm
18. Pawlotsky JM. 2012. New antiviral agents for hepatitis C. F1000 Biol. Rep. 4:5. http://dx.doi.org/10.3410/B4-5
19. Cooper C, Lawitz EJ, Ghali P, Rodriguez-Torres M, Anderson FH, Lee SS, Bédard J, Chauret N, Thibert R, Boivin I, Nicolas O, Proulx L. 2009. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol. 51:39-46. http://dx.doi.org/10.1016/j.jhep.2009.03.015
20. Shi ST, Herlihy KJ, Graham JP, Fuhrman SA, Doan C, Parge H, Hickey M, Gao J, Yu X, Chau F, Gonzalez J, Li H, Lewis C, Patick AK, Duggal R. 2008. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52:675-683. http://dx.doi.org/10.1128/AAC.00834-07
21. Shi ST, Herlihy KJ, Graham JP, Nonomiya J, Rahavendran SV, Skor H, Irvine R, Binford S, Tatlock J, Li H, Gonzalez J, Linton A, Patick AK, Lewis C. 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 53:2544-2552. http://dx.doi.org/10.1128/AAC.01599-08
22. Dvory-Sobol H, Xu S, Goodwin H, Goodman D, Svarovskaia ES, Miller MD, Mo H. 2011. Replication fitness and drug susceptibility of HCV triple class drug-resistant mutants; abstr. R-13. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, 22 to 23 June 2011
23. Dvory-Sobol H, Gontcharova V, Martin R, Lawitz EJ, McHutchison JG, Svarovskaia ES, Miller MD, Mo H. 2014. Low persistence of resistanceassociated variants after 3 days of monotherapy with NS5B NNI site II inhibitor GS-9669 in genotype 1 HCV patients. Abstr. 49th Ann. Meet. Eur. Assoc. Study Liver. http://www.natap.org/2014/EASL/EASL-74.htm.